Hypoxia-inducible factor-1A (HIF-1A) is a transcription factor that directly transactivates genes important for the growth and metabolism of solid tumors. HIF-1A is overexpressed in cancer, and its level of expression is correlated with patient mortality. Increased synthesis or stability of HIF-1A can be induced by hypoxia-dependent or hypoxia-independent factors. Thus, HIF-1A is expressed in both nonhypoxic and hypoxic cancer cells. The role of HIF-1A in nonhypoxiamediated cancer cell proliferation remains speculative. We have disrupted HIF-1a by targeted homologous recombination in HCT116 and RKO human colon cancer cells. Loss of HIF-1A significantly reduced nonhypoxia-mediated cell proliferation in vitro and in vivo. Paradoxically, loss of HIF-1A expression did not grossly affect the hypoxic compartments within tumor xenografts in vivo, although HIF-1A promoted cell proliferation and survival under hypoxia in vitro.
Introduction
Colorectal cancer is the second leading cause of cancer deaths in the United States. Colorectal cancer develops through multiple steps, with the sequential acquisition of genetic alterations in key tumor suppressors and oncogenes (1) . These genetic alterations in turn activate genes that support tumor proliferation and survival (2, 3) . Thus, a potential therapeutic approach against cancer is targeting the mediators of tumor growth and survival.
Hypoxia-inducible factor-1 (HIF-1) is strongly associated with cancer cell growth and survival (4) . HIF-1 is composed of the HIF-1a and HIF-1h subunits. Whereas HIF-1h is constitutively expressed, HIF-1a protein stability and synthesis are regulated by intratumoral hypoxia and genetic alterations (5) (6) (7) (8) (9) (10) (11) (12) . The HIF-1 complex transactivates hypoxia-responsive genes through binding to the hypoxia response elements (HRE) located on the promoter or enhancer regions of hypoxia-inducible genes (4, 5) . Promoter analyses for HRE show that HIF-1a directly transactivates >60 target genes, including those important for two universal characteristics of solid tumors: angiogenesis and glycolysis (4) .
HIF-1a is overexpressed in cancer, and its level of expression is correlated with patient mortality (13, 14) . However, further clarification of its role in tumorigenesis is required to determine if it is a valid therapeutic target (4) . For example, HIF-1a is generally a positive factor in tumor xenograft models (15) (16) (17) (18) (19) (20) (21) ). Yet, depending on the types of cells or tumor microenvironments tested, HIF-1a-deficient tumors have also been shown to grow faster than their wild-type counterparts (22, 23) .
In cancer cells, genetic alterations in key tumor suppressors or oncogenes increase synthesis or stability of HIF-1a, which in turn results in its expression under nonhypoxic conditions (8, (24) (25) (26) (27) . The literature has suggested that the genes induced via HIF-1a under nonhypoxic conditions are similar to those under hypoxia (9, 12, 24, (28) (29) (30) (31) . However, the functional consequences of HIF-1a expression on nonhypoxic cancer cell proliferation, glycolysis, and angiogenesis remain speculative (18, 32) . Furthermore, it remains unclear how the induction of HIF-1a by hypoxia-independent factors affects the compartments within a tumor (22, 33) .
In this article, we report that, in a subset of colon cancers, (a) HIF-1a promotes nonhypoxia-mediated cell proliferation in vitro and in vivo and (b) HIF-1a does not grossly affect the hypoxic compartments within tumor xenografts, although HIF-1a promotes cell proliferation and survival under hypoxic culture conditions.
Materials and Methods
Cell lines. HCT116 and RKO human colon cancer cells were acquired from the American Type Culture Collection (Manassas, VA) and cultured in recommended medium. Both cell lines harbor wild-type alleles of adenomatous polyposis coli (APC) and p53 (34, 35) . HCT116 cells harbor one mutated allele of b-catenin and K-Ras, which are wild-type in RKO cells (34, 36) . For normoxic culture conditions, cells were incubated at low confluence and 37jC in 5% CO 2 and room air (21% O 2 ). For hypoxic culture conditions, cells were incubated at low confluence and 37jC in a BBL GasPak 100 anaerobic system in which O 2 was f0.1% (BD Biosciences, Cockeysville, MD).
Real-time reverse transcription-PCR analyses. Real-time PCR reactions were done in triplicate on reverse transcription-derived cDNA as described previously (37) . Crossing point (CP) at which fluorescence increases appreciably above the background fluorescence was determined (37) . Gene expression relative to b-actin was calculated using the formula: ratio = 2 À[CPGene À CPh-actin] (38) .
Strategy for disruption of the human HIF-1a and vascular endothelial growth factor genes. The endogenous locus, adenoassociated virus (AAV) knockout construct, and resulting targeted locus are shown in Figs. 1A and 5A. The targeting strategy is as described previously (37, 39) . Exons 3 and 4 of HIF-1a or exon 2 of vascular endothelial growth factor (VEGF) were targeted for disruption with an AAV cassette containing the Neo resistance gene under the constitutive control of a SV40 promoter flanked by left and right homology arms f1 kb long. Successful disruption resulted in a 226-bp deletion (HIF-1a) or a 125-bp insertion (VEGF), with translation stop codons in all three reading frames. Cells exhibiting neomycin resistance were screened with locus-specific PCR. Once the first allele was successfully targeted, the Neo resistance gene was excised using Cre recombinase (Microbix Biosystems, Inc., Toronto, Ontario, Canada). The same targeting vector was then used to target the second allele. For locusspecific PCR to confirm homologous integration of the targeting vector, genomic DNA was amplified using primers specific for the targeted exons 3 and 4 (HIF-1a) or exon 2 (VEGF). Loss of HIF-1a was confirmed by Western blot analyses and loss of VEGF was confirmed by ELISA.
Western blot analyses. Whole-cell protein extracts were prepared from various cell lines, separated by electrophoresis, transferred to nitrocellulose membranes, and probed with antibodies as described previously (37) . Antibodies were obtained from BD Transduction Laboratories (San Jose, CA; mouse anti-human HIF-1a), Jackson Immunoresearch Laboratories (West Grove, PA; anti-mouse horseradish peroxidase), and Sigma (St. Louis, MO; a-tubulin). Antibody dilutions were as recommended by the manufacturer.
ELISA for VEGF. Equal numbers of cells were plated overnight. The VEGF protein level in the cultured medium was analyzed using the Quantikine VEGF ELISA kit (R&D Systems, Minneapolis, MN) following the manufacturer's protocol.
Measurements of cell proliferation, apoptotic index, and clonogenic survival. Cells were trypsinized, counted, and plated. For cell proliferation studies, cells were harvested daily for 5 days and stained with trypan blue, and viable (nonblue) cells counted on a hemocytometer. For calculations of apoptotic index, cells were harvested at days 3 to 5 and stained with Hoechst 33258, and nuclear morphology was scored (37) . Apoptotic index was calculated as the number of pyknotic nuclei divided by the total number of cells counted per Â100 power field. At least 10 fields were photographed and counted. For colony formation assays, cells were allowed to grow undisturbed for 2 weeks and stained with crystal violet.
Analyses of DNA content and 5-bromodeoxyuridine incorporation. For analyses of cellular DNA content, cells were harvested, permeated with 70% ice-cold ethanol, and stained with 50 Ag/mL propidium iodide in PBS containing 0.2% Tween 20 and 2.5 Ag/mL RNase. DNA content in 10,000 cells was measured on a FACSCalibur cytometer (Becton Dickinson, Franklin Lakes, NJ) and data were analyzed using Modfit Lt software (Verity Software House, Topsham, ME). For analyses of cellular incorporation of the halogenated DNA precursor 5-bromodeoxyuridine (BrdUrd), cells were labeled with 20 Ag/mL BrdUrd, fixed with 70% ice-cold ethanol, and stained with FITC-conjugated anti-BrdUrd antibody and propidium iodide using the BrdUrd cell detection kit (BD PharMingen, San Jose, CA). The intensity and distribution of cell-associated BrdUrd-FITC fluorescence were detected in 10,000 cells using a FACSCalibur cytometer.
Glycolysis assays. The parental and knockout cell lines were harvested at standardized concentrations and lysed by repeated freeze-thaw cycles. Intracellular ATP concentrations were measured using the ATP Assay kit (Biomedical Research Service Center at State University of New York, Buffalo, NY). In the presence of ATP, the enzyme luciferase catalyzes the oxidation of luciferin with concomitant emission of yellow green light. Measurements were made on a luminometer and compared with a standard curve of ATP concentrations. Cellular lactate or lactate dehydrogenase (LDH) concentrations were measured using the Lactate or LDH Assay kits (Biomedical Research Service Center). The assay is based on the reduction of the tetrazolium salt INT in a NADH-coupled enzymatic reaction to formazan, which exhibits an absorption maximum at 492 nm. Measurements were made on a spectrophotometer and compared with a standard curve of lactate or LDH. For each experiment, relative fold change in ATP or lactate was calculated by dividing each sample concentration by the concentration in HCT116 cells.
In vivo tumorigenesis. Cells were grown in standard conditions and harvested, and 5.0 Â 10 6 cells were implanted s.c. into the flanks of 6-weekold female athymic nu/nu mice (Charles River Laboratories, Wilmington, MA). Tumor sizes in two dimensions were measured with calipers, and volumes were calculated with the formula: (L Â W 2 ) Â 0.5, where L is length and W is width. To examine tumor blood flow, mice were given the fluorescent perfusion marker Hoechst 33342 (Sigma) 15 mg/kg per tail vein injection 3 minutes before sacrifice. To examine tumor cell proliferation, mice were given the DNA synthesis marker BrdUrd (Sigma) 1,500 mg/kg i.p. 2 hours before sacrifice (40) . I.p. injection of BrdUrd results in its uptake by proliferating cells, and bound BrdUrd can be detected in xenografts using antibody to BrdUrd. To examine intratumor hypoxia, mice were given the hypoxia marker pimonidazole 60 mg/kg i.p. 2 hours before sacrifice. Pimonidazole binds to the thiol-containing proteins specifically in hypoxic cells (41) . I.p. injection of pimonidazole results in its uptake by hypoxic tumor cells, and bound pimonidazole can be detected in xenografts using antibody to pimonidazole (41) . Mice were euthanized once overwhelmed by tumor burden or at the end of the study as defined by animal care guidelines. Tumor xenografts were quickly removed and frozen in liquid nitrogen or fixed in formalin. Mice were housed in barrier environments, with food and water provided ad libitum as approved by the University of Michigan Animal Care and Use Committee.
Immunohistochemistry. Tumor cryosections (10 Am thick) were cut with a Leica CM1900 cryostat. Formalin-fixed xenografts were paraffin embedded, sectioned, and stained with H&E by the University of Michigan Tissue Core Facility. Vasculature was stained using rat anti-mouse CD31 antibody (BD PharMingen; ref. 42) . Hoechst 33342 was visualized under a fluorescent microscope (42) . Bound pimonidazole was detected using the Hypoxyprobe-1 Plus kit (Chemicon International, Inc., Temecula, CA). Incorporated BrdUrd was detected using the BrdUrd In situ Detection kit (BD PharMingen). All antibody dilutions were according to the manufacturer's directions.
Statistics. In vitro studies were done in triplicate and repeated twice. In vivo studies were repeated once. Results are expressed as mean F SD of all experiments. Statistical analyses of data were done using Student's paired t test and Ps < 0.05 were considered significant.
Results
Targeted disruption of HIF-1a in HCT116 and RKO cells. Somatic cell knockout technology was used to generate HCT116 and RKO human colorectal cancer cell lines that were absent for HIF-1a expression. Exons 3 and 4 of HIF-1a were targeted for disruption as outlined in Fig. 1A . Homozygous disruption of HIF-1a was identified by genomic locus-specific PCR (Fig. 1B) . Loss of HIF-1a protein was confirmed by Western blot analysis using HIF-1a antibody (Fig. 1C) . The resulting cells, hereafter called HCT116 HIF-1a À/À or RKO HIF-1a À/À cells, are essentially identical with their respective parental HCT116 and RKO cells, with the exception of ablated HIF-1a expression. To control for clonal variation with passage, parental cells were passed in parallel with knockout cells and two independent clones of HIF-1a À/À cells were selected for further analyses.
To further confirm the disruption of HIF-1a, we measured the expression of four known HIF-1a target genes, the glucose transporter GLUT-1 and the glycolysis enzymes phosphofructokinase, aldolase, and LDH (4). Consistent with the literature, hypoxia induced the expression of these genes in both parental HCT116 and RKO cells (Fig. 1D) , whereas hypoxic induction of these genes was diminished in the HIF-1a À/À cells. Under normoxic conditions (21% O 2 ), phosphofructokinase and LDH showed decreased basal expression in HCT116
HIF-1a À/À cells. These latter findings support Figure 1 . Disruption of HIF-1a in colon cancer cells. A, disruption of HIF-1a . Endogenous HIF-1a locus, AAV knockout construct, and resulting targeted locus. Numbered boxes, exons; black boxes, targeted exons 3 and 4; ITR, inverted terminal repeats; HA, homology arm; P, SV40 promoter; Neo, neomycin resistance gene; pA, polyadenylate tail; striped triangles, loxP sites. B, confirmation of disruption of HIF-1a by locus-specific PCR. Primers P1 and P2, which amplify the targeted region in exons 3 and 4, are shown on the endogenous and targeted HIF-1a locus diagrams. Lane 2, endogenous locus contains a f296-bp fragment; lane 3, after successful targeting of the first allele and treatment with Cre recombinase, the amplification product is a smaller f190-bp fragment. With successful targeting of the second allele, the amplification product is a f1,950-bp fragment encompassing the Neo gene. C, confirmation of loss of HIF-1a by Western blot analysis. D, expression of HIF-1a target genes. GLUT-1, phosphofructokinase, LDH , and aldolase relative to b-actin by real-time reverse transcription-PCR are shown in noted cell lines and conditions (n = 9). *, P < 0.01, comparing the same cell line in hypoxia versus normoxia; **, P < 0.01, comparing HIF-1a À/À with HIF-1a +/+ clones in the same culture conditions. the notion that HIF-1a is expressed and may be functional in HCT116 cells under normoxia (9, 12, 24, (28) (29) (30) (31) .
Disruption of HIF-1a impairs cell proliferation and survival under hypoxic culture. Loss of HIF-1a led to significant decreases in cell proliferation and survival under hypoxia. Both HCT116
HIF-1a À/À and RKO HIF-1a À/À cells had at least 2-fold decreases in cell numbers compared with their parental cells when grown under hypoxia ( Fig. 2A) . Both HCT116 HIF-1a À/À and RKO HIF-1a À/À cells underwent marked apoptosis under hypoxia when compared with their parental cells (Fig. 2B) . These data reaffirm that HIF-1a promotes proliferation and survival in human colon cancer cells under hypoxic culture. Disruption of HIF-1a impairs cell proliferation in normoxic culture. Under normoxic conditions, faint levels of HIF-1a protein were observed in parental HCT116 and RKO cells (Fig. 1C) . Loss of HIF-1a resulted in a 3-fold decrease in HCT116 cell proliferation (Fig. 2C) . In contrast, loss of HIF-1a resulted in only a modest decrease in RKO cell proliferation (Fig. 2C) . We found no significant differences in apoptosis between parental and HIF-1a À/À cell lines under normoxic conditions (data not shown). Standard colony formation assays confirmed that under normoxic conditions, HCT116
HIF-1a À/À cells formed significantly smaller colonies compared with HCT116 cells (Fig. 2D) . The decreases in colony formation in RKO HIF-1a À/À cells were more subtle compared with RKO cells (Fig. 2D) . These results show, for the first time, that HIF1a is required for colon cancer cell proliferation in normoxic culture.
Disruption of HIF-1a impairs DNA synthesis and aerobic glycolysis in HCT116 but not RKO cells. We next examined the effects of HIF-1a on G 1 -S cell cycle progression. Hypoxia induced significant G 1 -S arrest in all cell lines tested as shown by the increases in G 1 -S ratios (Fig. 3A) . Loss of HIF-1a did not significantly alter the G 1 -S ratios in HCT116 cells grown under hypoxia, which was consistent with reports of HIF-1a-independent mechanisms in hypoxia-induced cell cycle arrest (43) . In contrast, loss of HIF-1a induced significant G 1 -S arrest in RKO cells (Fig. 3A) . Thus, cell cycle progression under hypoxic conditions can be HIF-1a dependent or HIF-1a independent.
Under normoxic culture conditions, loss of HIF-1a did not alter the G 1 -S ratio (Fig. 3A) , consistent with our proliferation data in RKO cells (Fig. 2C) . However, these findings were inconsistent with our observations that loss of HIF-1a significantly decreased normoxic proliferation in HCT116 cells (Fig. 2C) . To more directly examine DNA synthesis, we measured BrdUrd incorporation in HIF-1a À/À cells compared with parental cells. We found decreased incorporation of BrdUrd in HCT116 HIF-1a À/À cells compared with HCT116 cells in normoxia (Fig. 3B) . In contrast, incorporation of BrdUrd was equivalent in RKO HIF-1a À/À cells compared with RKO cells (Fig. 3B) . Thus, loss of HIF-1a impaired HCT116 cell proliferation under normoxia through decreased S-phase activity.
Because HIF-1a is well described to mediate anaerobic glycolysis (4), we hypothesized that HIF-1a may mediate aerobic glycolysis. Cancer cells may maintain high rates of aerobic glycolysis and produce increased levels of lactate even in the presence of oxygen, a phenomenon first described by Dr. Otto Warburg (44) . These glycolytic enzymes in turn may have a role in the cell cycle (45) . Recent reports have indicated that HIF-1a may be activated by aerobic glycolysis (8, 46) . We examined glycolysis under normoxic culture conditions by measuring ATP, lactate, and LDH. We found that loss of HIF-1a induced significant decreases in intracellular ATP, lactate, and LDH in HCT116 but not RKO cells (Fig. 3C-E) . These findings provide direct evidence that HIF-1a mediates aerobic glycolysis in HCT116 but not RKO cells. Taken together, these series of in vitro experiments reaffirm the notion that HIF-1a mediates cell proliferation and survival under hypoxia. Extending on the literature, these in vitro studies directly show that HIF-1a is essential for aerobic glycolysis and associated proliferation in HCT116 cells.
Disruption of HIF-1a impairs HCT116 but not RKO xenograft growth. To determine how disruption of HIF-1a affected tumors, we implanted parental and HIF-1a À/À cells into the flanks of athymic nude mice and examined the ensuing xenografts. HCT116 HIF-1a À/À xenografts exhibited marked delays in growth compared with HCT116 xenografts (Fig. 4A) . After 18 days of growth, HCT116
HIF-1a À/À xenograft volumes were up to 8-fold less than HCT116 xenograft volumes. In contrast, no significant differences in volumes were noted between RKO HIF-1a À/À and parental RKO xenografts (Fig. 4B) . These findings were surprising and suggested that the role of HIF-1a in normoxic cell proliferation in vitro may be more predictive of its functional significance in vivo.
Disruption of HIF-1a impairs proliferation in the nonhypoxic compartments of HCT116 xenografts. It is generally accepted that a tumor is composed of three compartments: the nonhypoxic compartment composed of proliferating cells, the hypoxic compartment composed of quiescent cells, and the anoxic compartment composed of necrotic cells (33, 47) . To distinguish the role of HIF-1a in these tumor compartments, we determined tumor microvessel density (MVD), blood flow, functional hypoxia, and cellular proliferation. MVD was determined by staining with antibodies to the endothelial cell marker CD31. Tumor blood flow was determined by the diffusion of i.v. given Hoechst 33342. Functional hypoxia was determined by tumor uptake of the hypoxia marker pimonidazole. Cell proliferation was determined by cell incorporation of the DNA synthesis marker BrdUrd.
Consistent with a previous report (16) , the presence or absence of HIF-1a did not significantly affect MVD as measured by CD31 staining or tumor blood flow as measured by Hoechst 33342 uptake (Fig. 4C, rows 1 and 2 ). As such, the areas of functional hypoxia, as determined by pimonidazole staining, were equivalent in HIF-1a +/+ and HIF-1a À/À xenografts (Fig. 4C, row 4) . Consistent with our in vitro data that hypoxia induced G 1 -S arrest, the pimonidazole-positive cells did not incorporate BrdUrd, which indicated that they were concomitantly quiescent (asterisks in Fig. 4C, row 4 versus row 5) . These findings allude to the possibility that HIF-1a expression may not maintain or expand the hypoxic compartment within tumors in vivo.
We next determined whether HIF-1a expression affected the nonhypoxic compartment of xenografts. The nonhypoxic compartments were mapped according to two variables: the active incorporation of BrdUrd and the concomitant lack of pimonidazole incorporation (33, 41, 47) . Compared with parental HCT116 xenografts, HCT116
HIF-1a À/À xenografts had decreased proliferation within the nonhypoxic compartments as shown by significantly diminished BrdUrd uptake in the pimonidazole-negative regions (Fig. 4C, row 5 ). In contrast, there was equivalent BrdUrd incorporation and proliferation within the nonhypoxic compartments of RKO and RKO HIF-1a À/À xenografts (Fig. 4C, row 5) . Thus, HIF-1a promotes proliferation in the nonhypoxic compartments of HCT116 but not RKO xenografts.
Altogether, these series of in vivo experiments show that in a subset of colon cancers, HIF-1a is essential for cell proliferation within the nonhypoxic compartments of tumors. Surprisingly, HIF1a may not be essential for maintaining the hypoxic compartment of tumors in vivo. This observation is particularly perplexing, given the fact that HIF-1a was essential for cell proliferation and survival under hypoxic conditions in vitro. A potential explanation is that the regions of hypoxia within a tumor are small. Thus, perturbations in these small regions of hypoxia may not significantly affect tumor volume. If this were the case, then expanding the hypoxic compartments within the xenografts may unveil a more significant contribution from HIF-1a.
Disruption of HIF-1a and VEGF in HCT116 and RKO xenografts. To determine whether expansion of the tumor hypoxic compartments would alter the growth of HIF-1a-deficient xenografts, we ablated VEGF gene expression. As VEGF is a dominant tumor angiogenic factor (48, 49) , we reasoned that loss of VEGF would effectively inhibit tumor angiogenesis, thus converting tumor nonhypoxic compartments to hypoxic and anoxic compartments. We proceeded to disrupt the VEGF gene by targeted homologous recombination (Fig. 5A) . Disruption of VEGF was confirmed by genomic locus-specific PCR (data not shown). Loss of VEGF was confirmed by ELISA and loss of HIF-1a was reconfirmed by Western blot analyses ( Fig. 5B and C) . In vitro, presence or absence of VEGF did not alter cell proliferation (data not shown).
Disruption of HIF-1a does not alter the hypoxic compartments within VEGF -disrupted xenografts. As expected, HCT116
VEGF À/À and RKO VEGF À/À xenograft volumes were decreased by 5-to 10-fold compared with their respective parental HCT116 and RKO xenografts ( Fig. 5D and E) . The growth of VEGFdisrupted xenografts were suppressed due to expansion of the tumor hypoxic compartments, which is consistent with the extensive literature (50) . Indeed, the VEGF-disrupted xenografts exhibited up to 90% decreases in tumor MVD and blood flow. 7 This was consistent with the marked increase in tumor regions with pimonidazole uptake (Fig. 4D compared with Fig. 4C, row 4) . Thus, as expected, disruption of VEGF led to significant expansion of the tumor hypoxic compartments and growth delay.
HCT116 VEGF À/ÀHIF-1a À/À xenografts were significantly smaller than HCT116
HIF-1a À/À , and HCT116 xenografts (Fig. 5D) . However, the tumor hypoxic compartments were equivalent between HCT116
VEGF À/ÀHIF-1a À/À and HCT116
VEGF À/À xenografts (Fig. 4D) . Thus, HIF-1a did not affect the hypoxic compartments, and again, loss of HIF-1a selectively compromised the nonhypoxic compartment in HCT116 xenografts. As such, the negative effects of HIF-1a disruption on nonhypoxia-mediated proliferation were additive with the growth suppressive effects of VEGF disruption. Hence, in HCT116 xenografts, the effects of HIF-1a and VEGF are independent and additive. These data provide a mechanism and preliminary ''proof-of-principle'' that inhibition of HIF-1a is additive with inhibition of VEGF. Furthermore, these data support the conclusion that HIF-1a is essential for the nonhypoxic rather than the hypoxic compartments in HCT116 xenografts. (Fig. 4D versus Fig. 4C, row 4) , the presence or absence of HIF-1a did not alter tumor pimonidazole uptake or volume (Figs. 4D and 5E respectively, RKO VEGF À/ÀHIF-1a À/À versus RKO VEGF À/À ). These findings support the conclusion that HIF-1a may not be essential for the gross maintenance of tumor hypoxic compartments.
Discussion
As with previous studies that report the effects of HIF-1a using established cell lines, our data should be interpreted within the tumor-specific genetic alterations of the cells studied. It is also important to note that although our findings within the in vivo nonhypoxic compartments are consistent with our in vitro findings under normoxia, it remains unknown how in vivo and in vitro oxygen tensions may correlate. With these caveats in mind, several novel conclusions can be drawn from this study.
First, HIF-1a is a positive regulator of cell proliferation in HCT116 cells grown in normoxic culture in vitro. Furthermore, HIF-1a mediates the Warburg effect in HCT116 cells. To our knowledge, these are the first data to directly demonstrate the role of HIF-1a on aerobic glycolysis and cell proliferation in a , and RKO VEGF À/ÀHIF-1a À/À cells (E; n = 20). *, P < 0.01, comparing parental cells with both clones of HIF-1a À/À xenografts at the same time point; **, P < 0.01, comparing parental cells with both clones of VEGF À/À xenografts at the same time point; ***, P < 0.01, comparing HIF-1a À/À xenografts with VEGF À/À HIF-1a À/À xenografts at the same time point; ****, P < 0.01, comparing VEGF À/À xenografts with VEGF human colon cancer cell line. These findings are consistent with the literature that HIF-1a is a positive growth factor that is regulated by oncogenic mutations. Second, HIF-1a is a positive regulator of cell proliferation within the nonhypoxic compartments of HCT116 xenografts in vivo. Furthermore, in these tumors, disruption of HIF-1a is additive with disruption of VEGF in suppressing growth. To our knowledge, these are the first data to demonstrate the role of HIF-1a in the proliferative compartment of certain tumors. Furthermore, the biological effects of HIF-1a and VEGF can be independent and additive.
Third, although HIF-1a is absolutely essential for cell proliferation and survival under hypoxia in vitro, it does not grossly contribute to the bulk of the hypoxic compartments in this subset of xenografts. That HIF-1a is essential for cell proliferation and survival under hypoxia in vitro is consistent with previous reports. The finding that HIF-1a does not grossly contribute to the hypoxic compartment in vivo would suggest that either compensatory or cooperating mechanisms are activated in these tumors. Thus, other factors may need to be disrupted to appreciate the global effects of HIF-1a within the hypoxic compartments of xenografts.
A potential clinical implication from these data is that therapy with anti-HIF-1a agents may be effective against tumors in which HIF-1a contributes to nonhypoxic cell proliferation. Moreover, in this subset of tumors, anti-HIF-1a therapy may be additive with antiangiogenic therapy. Certainly, further investigations are warranted and ongoing. The mechanisms by which HIF-1a regulates aerobic glycolysis and cell proliferation are not fully delineated. The cell-specific mechanisms that render a cell dependent or independent on HIF-1a remain to be determined. The mechanisms by which cells compensate in the absence of HIF-1a are not yet identified. Nevertheless, these are the first data to directly show that HIF-1a regulates nonhypoxia-mediated proliferation in colon cancer cells and xenografts.
